03/06/20
Bell Potter rates ((CYC)) as Buy (1) –
Cyclopharm has taken steps towards getting regulatory approval from the US, filing for a 505(b)2 registration for Technegas.
Technegas is helpful for diagnosing covid-19 patients with acute respiratory distress syndrome and aids in understanding how much a patient’s respiratory has been impacted.
The company raised $9.7m in December 2019 with the funds used to establish US operations later this year. Revenue estimates have been reduced for FY20-21 due to delay in launching the US operations.
Bell Potter leaves the rating unchanged at Buy along with an unchanged target of $1.77.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
77.0¢ |
Change
-0.070(8.33%) |
Mkt cap ! $85.57M | |||
| Open | High | Low | Value | Volume |
| 84.0¢ | 84.0¢ | 75.5¢ | $160.3K | 200.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2999 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 79.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2025 (20 minute delay) ? |
| CYC (ASX) Chart |